Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever. All key data samples have been collected following dosing of all subjects in the Phase 2a (prophylactic) trial as part of…
Description During a fireside chat with analysts from Brookline Capital Markets, Radiopharm Theranostics’ (ASX:RAD) CEO Riccardo Canevari provided clinical…
Lightning Minerals (L1M or the Company) is delighted to announce the discovery of spodumene within a lithium bearing pegmatite…
Gunnison Copper (TSX:GCU,OTCQB:EXMGF) is shifting its development strategy for the Gunnison copper project in Arizona, US, laying out plans…
Provaris Energy Ltd (ASX.PV1, Provaris, the Company) is pleased to present the notice of initial substantial holder. Click here…
Group Eleven Resources Corp. (TSXV: ZNG) (OTC Pink: GRLVF) is pleased to announce its participation at the upcoming New…
HIGHLIGHTS 27m @ 2.7 grams per tonne (‘g/t’) gold equivalent (AuEq.), including 12m @ 3.9 g/t AuEq. from 435m…
/NOT FOR DISTRIBUTION TO UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ TSX Venture Exchange (TSX-V): LIT Frankfurt Stock Exchange…
Within 24.51m of 486.30 g/t AgEq Silver47 Exploration Corp. (TSXV: AGA) (‘Silver47’ or the ‘Company), is pleased to announce…